Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk
Analytical and Bioanalytical Chemistry · 2024
DOI: 10.1007/s00216-024-05496-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical and Bioanalytical Chemistry, 2024. Verfasst von Anna B Hansson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Unit of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Aminophenols, Milk, Human, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.
Abstract (Originalsprache)
The four cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators, ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have revolutionised the treatment of CF by direct action on the protein target behind the disease’s development. The aim was to develop and validate a quantification method for these CFTR modulators in plasma and breast milk to better understand inter-patient variability in pharmacokinetics and treatment outcome, including the risk of adverse drug reactions. The ability to monitor CFTR modulators in breast milk enables the estimation of the exposure of breastfed infant, with a potential concern for CFTR modulator-induced liver injury. The analysis was performed on a Thermo Vanquish Flex Binary UHPLC system coupled to a high-resolution mass spectrometer (HRMS), Thermo Q Exactive. The analytes were detected using positive electrospray ionisation in full scan mode. After sample preparation by protein precipitation, the supernatant was injected onto the LC system and the analytes were separated using a Zorbax SB-C18 Rapid Res HPLC column (3.5 µm, 4.6 × 75 mm). This is the first published method for CFTR modulators in breast milk. The validated quantification range for ivacaftor is 0.0050–10 µg/mL with a coefficient of variation < 6% and a mean accuracy of 97–106%; for lumacaftor, tezacaftor, and elexacaftor, the validated quantification range is 0.050–100 µg/mL with a coefficient of variation < 8% and a mean accuracy 93–106%. A simple and sensitive quantification method for CFTR modulators has been developed and used for routine analysis of human plasma and breast milk samples since 2022. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Unit of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, Solna, Sweden.
- Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge, Sweden.
- Stockholm CF Centre, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Huddinge, Sweden.
- Medical Unit of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. victoria.barclay@regionstockholm.se.
Förderung
- Karolinska Institute
Zitieren
APA
Hansson, A. B., Wadström, H., Eliasson, E., Al Shakirchi, M., de Monestrol, I., & Barclay, V. (2024). Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk. Analytical and Bioanalytical Chemistry. https://doi.org/10.1007/s00216-024-05496-2
Vancouver
Hansson AB, Wadström H, Eliasson E, Al Shakirchi M, de Monestrol I, Barclay V. Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk. Analytical and Bioanalytical Chemistry. 2024. doi:10.1007/s00216-024-05496-2
BibTeX
@article{Hansson2024,
author = {Hansson, Anna B and Wadström, Hjalmar and Eliasson, Erik and Al Shakirchi, Mahasin and de Monestrol, Isabelle and Barclay, Victoria},
title = {Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk},
journal = {Analytical and Bioanalytical Chemistry},
year = {2024},
doi = {10.1007/s00216-024-05496-2}
}
EUVIMED